SCHEMBL23607126

SCHEMBL23607126

O=C(Nc1c[nH]c(=O)c(N2CCNCC2)n1)c1ccccc1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.39
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ RAB9A P51151 5/20 0.39
▸ LMNA P02545 5/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ HTT P42858 5/20 0.38
▸ TP53 P04637 4/20 0.38
▸ HPGD P15428 4/20 0.38
▸ HSD17B10 Q99714 4/20 0.38
▸ GAA P10253 2/20 0.38
▸ BACE1 P56817 4/20 0.38
▸ ALPL P05186 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ BRPF1 P55201 1/20 0.37
▸ CCNC P24863 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ RCE1 Q9Y256 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23607127 0.84 PIM1 (0.44) —
SCHEMBL23607125 0.77 PRKCA (0.46) NPC1MEN1KMT2ARAB9ALMNA
SCHEMBL25131888 0.76 LMNA (0.45) NPC1MEN1KMT2ARAB9ALMNA
SCHEMBL23607113 0.70 NPC1 (0.57) NPC1MEN1KMT2ARAB9AKDM4E
SCHEMBL23607117 0.66 NPC1 (0.51) NPC1MEN1KMT2ARAB9AALDH1A1
SCHEMBL13116729 0.65 ALDH1A1 (0.61) MEN1KMT2ALMNAKDM4EHTT
SCHEMBL23607115 0.64 LMNA (0.43) NPC1RAB9ALMNAKDM4EHTT
SCHEMBL10757233 0.63 MEN1 (0.51) NPC1MEN1KMT2ARAB9ALMNA
SCHEMBL25132256 0.62 PIM1 (0.49) —
SCHEMBL27903794 0.62 HSD17B10 (0.60) NPC1MEN1KMT2AKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103415-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
WO-2021133917-A1 SMARCA INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103415-A1 SMARCA INHIBITORS AND USES THEREOF SMARCC1, SMARCE1, SMARCA1 NPC1 2800/4885MEN1 1840/4885KMT2A 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback